Pivotal Study of MRI-guided Transurethral US Ablation to Treat Localized Prostate Cancer

Pivotal Study of MRI-guided Transurethral US Ablation to Treat Localized Prostate Cancer

A prospective, multi-center, single-arm study, planned in 110 patients. The primary objective of the study is to further evaluate the safety and efficacy of a magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy system (TULSA-PRO) intended to ablate prostate tissue of patients with localized, organ-confined prostate cancer.

For More Detailed Information, Contact:

• Steve S. Raman, MD, FSAR, FSIR, Principal Investigator
• Tammy Floore, BSN, MBA,  310-481-7510,  tfloore@mednet.ucla.edu   
• If interested, please check out the patient pamphlet and eligibility criteria. http://radiology.ucla.edu/clinical-trials
• ClinicalTrials.gov identifier: NCT02766543